Characteristics | Â | Oct4 | Â | NEAT1 | Â | MALAT1 | Â | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | Normal | Overexpression | Â | Normal | Overexpression | Â | Normal | Overexpression | Â | |||||||
n | n | (%) | n | (%) | P a | n | (%) | n | (%) | P a | n | (%) | n | (%) | P a | |
Overall | 124 | 18 | (14.5) | 106 | (85.5) | Â | 12 | (9.7) | 112 | (90.3) | Â | 14 | (11.3) | 110 | (88.7) | Â |
Tumor stage | ||||||||||||||||
 I + II | 72 | 16 | (22.2) | 56 | (77.8) | 0.005 | 11 | (15.3) | 61 | (84.7) | 0.014 | 12 | (16.7) | 60 | (83.3) | 0.028 |
 III + IV | 51 | 2 | (3.9) | 49 | (96.1) |  | 1 | (2.0) | 50 | (98.0) |  | 2 | (3.9) | 49 | (96.1) |  |
T stage | ||||||||||||||||
 I + II | 104 | 18 | (17.3) | 86 | (82.7) | 0.050 | 11 | (10.6) | 93 | (89.4) | 0.473 | 13 | (12.5) | 91 | (87.5) | 0.361 |
 III + IV | 19 | 0 | (0.0) | 19 | (100.0) |  | 1 | (5.3) | 18 | (94.7) |  | 1 | (5.3) | 18 | (94.7) |  |
N stageb | ||||||||||||||||
 0 | 71 | 15 | (21.1) | 56 | (78.9) | 0.021 | 11 | (15.5) | 60 | (84.5) | 0.014 | 12 | (16.9) | 59 | (83.1) | 0.029 |
 1 + 2 | 50 | 3 | (6.0) | 47 | (94.0) |  | 1 | (2.0) | 49 | (98.0) |  | 2 | (4.0) | 48 | (96.0) |  |
M stagec | ||||||||||||||||
 0 | 116 | 18 | (15.5) | 98 | (84.5) | 0.259 | 12 | (10.3) | 104 | (89.7) | 0.370 | 14 | (12.1) | 102 | (87.9) | 0.329 |
 1 | 7 | 0 | (0.0) | 7 | (100.0) |  | 0 | (0.0) | 7 | (100.0) |  | 0 | (0.0) | 7 | (100.0) |  |
NEAT1 | ||||||||||||||||
 Normal | 12 | 10 | (83.3) | 2 | (16.7) | <0.001 | − | − | − | − | − | − | − | − | − |  |
 Overexpression | 112 | 8 | (7.1) | 104 | (92.9) |  | − | − | − | − |  | − | − | − | − |  |
MALAT1 | ||||||||||||||||
 Normal | 14 | 10 | (71.4) | 4 | (28.6) | <0.001 | 11 | (78.6) | 3 | (21.4) | <0.001 | − | − | − | − |  |
 Overexpression | 110 | 8 | (7.3) | 102 | (92.7) |  | 1 | (0.9) | 109 | (99.1) |  | − | − | − | − |  |